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Summary Previous evidence in an animal model of drug self-administration and drug seeking
showed that acute oxytocin decreased methamphetamine (meth) seeking in male rats, suggesting
potential clinical efficacy for the treatment of psychostimulant addiction. However, based on the
well-established role of oxytocin in reproduction and pair bond formation, it is important to know
how this effect extrapolates to females. Here, we tested whether oxytocin (1 mg/kg, IP) would
decrease meth seeking in female rats across various stages of the estrous cycle (Experiment 1).
Freely cycling Long Evans female rats self-administered meth (IV) in 2-h daily sessions, followed
by daily extinction sessions. Following extinction, rats received oxytocin (0, 0.3, or 1 mg/kg, IP)
30 min before a meth priming injection (1 mg/kg, IP) to assess reinstatement of meth seeking.
Next, we examined the effects of oxytocin on motivated meth- and sucrose-taking and seeking in
male and female rats. In separate experiments, males and females self-administered meth
(Experiment 2) or sucrose (Experiment 3) until responding was stabilized along a fixed ratio (FR) 5
schedule of reinforcement. Subsequently, rats received either oxytocin or vehicle prior to self-
administration along a progressive ratio (PR) schedule of reinforcement. Rats were subsequently
tested for cue-, meth-, and stress-induced reinstatement after pretreatment with oxytocin or
vehicle. While oxytocin reduced meth seeking in females, we found that estrous cycle stage (as
determined from vaginal cytology) did not influence meth-primed reinstatement or the ability of
oxytocin to decrease reinstatement of meth seeking. Oxytocin reduced PR responding for meth
only in females. Females responded more than males during cue-induced reinstatement of meth
and sucrose seeking, and oxytocin reduced this responding only in meth females. In both sexes,
oxytocin attenuated meth seeking in response to a meth prime and yohimbine (a pharmacological
stressor). The results suggest that oxytocin may have efficacy as a treatment of meth addiction in
both sexes; however, females may show greater response to oxytocin treatment for the
prevention of relapse.
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Oxytocin is an endogenous peptide that is primarily synthe-
sized in magnocelluar neurons of the supraoptic and para-
ventricular nuclei of the hypothalamus and is secreted
through the posterior pituitary for systemic circulation.
In addition, oxytocin is produced in parvocelluar neurons
in the paraventicular nucleus, which project to various
brain regions. Oxytocin binds to the Gq class of G pro-
tein-coupled receptors activating phopholipase C and sub-
sequently increasing neuronal firing and neurotransmitter
release through this second messenger cascade (Gimpl and
Fahrenholz, 2001). In both males and females, central
oxytocin regulates social and sexual bonding, as well as
other behaviors such as aggression, stress, and anxiety
(Baskerville and Douglas, 2010). In females, systemic oxy-
tocin plays an important role in reproduction by inducing
uterine contractions for childbirth and facilitating lacta-
tion. Oxytocin receptors are distributed throughout the
brain (Gimpl and Fahrenholz, 2001), including regions of
the mesocorticolimbic dopamine system critically involved
in reward processing (Baskerville and Douglas, 2010). For
example, oxytocin fibers innervate dopamine-containing
nuclei in the ventral tegmental area. Cell bodies of dopa-
mine neurons that make up the mesocorticolimbic dopa-
mine pathways originate in this area, suggesting that
oxytocin may subsequently affect dopamine release into
target regions (e.g., nucleus accumbens, amygdala, pre-
frontal cortex). Additionally, hypothalamic oxytocin cells
express dopamine receptors (Baskerville et al., 2009),
suggesting that dopamine may mediate oxytocin release.
Combined, this extensive interaction of the dopamine and
oxytocin systems has expanded the interest in the role of
oxytocin in drug addiction.
Based on such evidence, oxytocin has potential for treat-
ment of psychostimulant addiction (McGregor and Bowen,
2012) and may play a regulatory role in attenuating drug
tolerance, dependence, and withdrawal via actions in the
mesolimbic dopamine reward pathways (Baskerville and
Douglas, 2010). Oxytocin blocked cocaine-induced dopa-
mine release in the nucleus accumbens (Kovacs et al.,
1990) and decreased cocaine intake during self-administra-
tion (Sarnyai and Kovacs, 1994). Additionally, recent pre-
clinical evidence suggests that oxytocin may have
therapeutic benefits in preventing relapse to methamphe-
tamine (meth) use (Carson et al., 2010a). Of particular note,
oxytocin decreased meth seeking in an animal model of
addiction (Carson et al., 2010a) and reduced meth-condi-
tioned reward (Qi et al., 2009; Baracz et al., 2012) in males.
Oxytocin may be a critical regulator in drug addiction via
modulation of dopaminergic transmission in corticolimbic
structures (Baskerville and Douglas, 2010; Sarnyai and
Kovacs, 1994). For example, oxytocin decreased dopamine
release and receptor binding in mesolimbic brain structures
(Sarnyai and Kovacs, 1994). Support for the use of oxytocin as
an addiction treatment has gained momentum, due in part to
the ability of some drugs to enhance social interactions
(McGregor et al., 2008; Dumont et al., 2009). Further, neural
circuits mediating social bonding and drug reward may over-
lap (Burkett and Young, 2012).
To date, the ability of oxytocin to ameliorate meth
seeking or conditioned reward in female rats is unknown.However, this is an important question given that gonadal
hormones regulate oxytocin’s binding affinity and receptor
density in various brain regions (Schumacher et al., 1990;
Patchev et al., 1993). Further, progesterone and estrogen
fluctuate throughout the estrous cycle in female rats,
rendering studies with females a necessity to determine
oxytocin’s full potential as a pharmacotherapeutic treat-
ment for meth addiction. Clinical research in meth addic-
tion indicates numerous sex differences in terms of meth
use patterns and response to treatment (reviewed in Dlu-
zen and Liu, 2008). For example, women tend to initiate
meth use at a younger age (Dluzen and Liu, 2008), transi-
tion faster to dependence, exhibit greater dependence
(Rawson et al., 2005), and have greater comorbidity with
other neuropsychiatric disorders (Hser et al., 2005; Yen
and Chong, 2006). While clinical evidence has shown gen-
der differences, preclinical research investigating meth
addiction and potential pharmacotheraputic treatments
has primarily focused only on male subjects. This pattern
is problematic, as females may respond differently to
treatments when compared to males, suggesting a need
for gender-specific therapies. Consistent with clinical
populations, animal models indicate that female rodents
have an increased sensitivity to meth’s psychomotor
stimulating effects (Schindler et al., 2002; Milesi-Halle
et al., 2007).
Animal models of drug self-administration incorporate
various aspects of the addiction cycle, including motivation
to consume a drug and/or drug seeking behavior in the
absence of reinforcement. Self-administration models
require animals to learn to press an operandum (typically
a lever) for an intravenous drug infusion. In these models,
more female rats acquire meth self-administration relative
to males (Roth and Carroll, 2004), exhibit higher meth intake
(Reichel et al., 2012), and exert more effort for meth as a
primary reward (Roth and Carroll, 2004). Meth seeking can be
inferred by the reinstatement of lever responding following a
period of non-reinforced responding. These reinstatement
tests incorporate various trigger factors (e.g., cues, drug-
priming, or stress) for the testing of pharmacotherapies that
may block reinstatement (Yahyavi-Firouz-Abadi and See,
2009).
Here, we assessed whether systemic oxytocin may be a
potential treatment for meth addiction in females and
males. To this end, we first determined the effects of
oxytocin (0.3 and 1 mg/kg) on meth-primed reinstatement
of meth seeking throughout the various stages of the
estrous cycle in female rats. Second, we determined
whether oxytocin (1 mg/kg, the dose previously shown
to reduce meth-primed reinstatement in females) would
impact motivation for meth in both males and females
during meth self-administration and in response to meth
associated cues, meth priming, or pharmacological stress
(yohimbine) induced reinstatement. We utilized yohimbine
(an a2-adrenergic receptor antagonist) as a pharmacologi-
cal stressor as it can elicit anxiety states in clinical studies
(Bremner et al., 1996), craving in drug dependent subjects
(Greenwald et al., 2013), and reinstatement of drug
seeking in rats (See and Waters, 2010). Finally, we deter-
mined whether oxytocin effects would extend to natural
reinforcement (i.e., sucrose pellets) in males and
females.
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2.1. Subjects
A total of 22 male and 39 female Long—Evans rats (Charles
River, Raleigh, NC) weighing 250—300 g and 180—200 g,
respectively, at the time of arrival, were used. All rats were
individually housed on a reversed 12:12 light—dark cycle in a
temperature and humidity controlled vivarium. Water was
available ad libitum throughout the study and rat chow
(Harlan, Indianapolis, IN, USA) was provided daily until SA
stabilized, after which time food was provided ad libitum. All
experimental procedures were approved by the Institutional
Animal Care and Use Committee of the Medical University of
South Carolina and were in accordance with the ‘‘Guide for
the Care and Use of Laboratory Rats’’ of the Institute of
Laboratory Animal Resources on Life Sciences, National
Research Council.
2.2. Surgery and drugs
Rats were anesthetized with IP injections of ketamine
(66 mg/kg; Vedco Inc, St. Joseph, MO, USA), xylazine
(1.3 mg/kg; Lloyd Laboratories, Shenandoah, IA, USA), and
equithesin (0.5 ml/kg; sodium pentobarbital 4 mg/kg,
chloral hydrate 17 mg/kg, 21.3 mg/kg magnesium sulfate
heptahydrate dissolved in 44% propylene glycol, 10% ethanol
solution). Ketorolac (2.0 mg/kg, IP; Sigma Chemical, St.
Louis, MO) was given before surgery as an analgesic. Cathe-
ters (constructed with Silastic tubing, Dow Corning Corpora-
tion, Midland, MI) were inserted 33 mm into the right jugular
vein and secured with silk sutures. The opposite end ran
subcutaneously and exited through a small incision on the
back below the shoulder blades and was attached to an
infusion harness (Instech Solomon, Plymouth Meeting, PA).
During recovery from surgery, catheters were flushed once
daily for 5 days with 0.1 ml of Timentin (24 mg/0.1; Glax-
oSmithKline, Research Triangle Park, NC) and 10 U/ml of
heparinized saline (Elkins-Sinn, Cherry Hill, NJ). During meth
self-administration (methamphetamine hydrochloride;
Sigma Chemical, St. Louis, MO), catheters were flushed with
0.1 ml of 10 U/ml heparinized saline before and after every
self-administration session. Catheter patency was periodi-
cally verified with methohexital sodium (10 mg/ml dissolved
in 0.9% saline; Sigma Chemical, St. Louis, MO), a short acting
barbiturate that produces a rapid loss in muscle tone when
administered intravenously. Oxytocin (1 mg/ml dissolved in
ddH2O; Cell Sciences, Canton, MA) was administered prior to
progressive ratio (PR) and reinstatement testing and yohim-
bine hydrochloride (2.5 mg/ml dissolved in ddH2O; Sigma
Chemical, St. Louis, MO) was used for stress-induced rein-
statement.
2.3. Self-administration
Self-administration procedures were based on recent studies
of meth self-administration in males (Reichel et al., 2012;
Reichel and See, 2010). All self-administration experiments
were conducted during the rats’ dark cycle in standard
Plexiglas self-administration chambers (30  20  20 cm)
that were enclosed in sound attenuating cubicles with aventilation fan (Med Associates, St. Albans, VT) and linked
to a computerized data collection program (MED PC, Med
Associates). Each chamber was equipped with two retract-
able levers with a white stimulus light above each lever,
house light, and tone generator. For meth self-administra-
tion, infusion tubing enclosed in steel spring leashes (Plastics
One Inc., Roanoke, VA) was connected to the infusion harness
and a weighted swivel apparatus (Instech, Plymouth Meeting,
PA) was suspended above the box to allow for free movement
within the chamber.
Self-administration sessions were conducted 6 days/week
to criterion (14 sessions > 10 infusions). The house light
remained on throughout the sessions and a response on
the active lever resulted in activation of the pump and
delivery of a 2-s meth infusion (17.5 mg/50 ml bolus for
females and 20 mg/50 ml bolus for males) and a 5-s presenta-
tion of a stimulus complex (illumination of the white stimulus
light over the active lever and activation of tone generator;
78 dB, 4.5 kHz), followed by a 20-s time-out. During the time-
out period, responses on the active and inactive levers were
recorded, but had no scheduled consequences.
2.4. Progressive ratio schedule of reinforcement
PR tests were conducted when stable self-administration was
evident based on the criteria of 14 days with more than 10
reinforcers earned. Before tests, rats were injected with
oxytocin (1 mg/kg) or vehicle. Test order was counterba-
lanced, and between tests, rats received a minimum of 2
self-administration sessions. During these tests, reinforce-
ment was contingent upon an increasing number of responses
which incrementally increased through the following pro-
gression: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95,
118, 145, 178, 219, 268, 328, 402, 492, 603 (Richardson and
Roberts, 1996). Lever presses, infusions, and breakpoints
were assessed for each test. Breakpoint was defined as the
highest number of lever presses required by the rat to receive
a single infusion. The session terminated if a rat failed
to receive an infusion or sucrose pellet for 1 h or after a
total of 5 h.
2.5. Extinction and reinstatement
Following self-administration, rats underwent 2 h daily
extinction sessions for a minimum of 10 days, where
responses on both the active and inactive levers were
recorded, but had no scheduled consequences. Extinction
criterion consisted of <25% responding on the active lever
relative to the last 5 days of self-administration. Upon reach-
ing criteria, rats underwent cue-, meth-, and yohimbine-
induced reinstatement testing. Prior to all reinstatement
tests, rats received either an injection of oxytocin (0.3 or
1 mg/kg) or vehicle (IP) 30 min before testing (see specific
experimental methods detailed below). For cue-induced
reinstatement, responding on the active lever resulted in
presentation of the light + tone stimulus complex along a FR 5
schedule of reinforcement, whereby 5 lever presses were
required to receive the stimulus complex. For drug-primed
reinstatement tests an injection of meth (1 mg/kg dissolved
in 0.9% physiological saline, IP) was given immediately prior
to testing. Prior to stress-induced reinstatement tests, an
2346 B.M. Cox et al.injection of yohimbine hydrochloride (2.5 mg/kg, IP) was
given after oxytocin or vehicle, 30 min prior to testing.
During both meth-primed and yohimbine-induced reinstate-
ment tests, responses on either lever were recorded, but did
not elicit any programmed consequences. Between all rein-
statement tests, rats experienced a minimum of 2 extinction
sessions, or until extinction criterion was met.
2.6. Estrous cycle monitoring
Female rats were habituated to vaginal cytology procedures
during self-administration. Vaginal lumen samples were col-
lected by gently flushing 30 ml of ddH2O with a sterile saline-
dipped pipette tip and extracting the sample using a micro-
pipette before rats were placed in the self-administration
chambers. Collected samples were smeared on to a glass
slide, stained with Quik-Dip Hematology Stain (Mercedes
Medical, FL), and examined for classification of cycle phase
(estrus, proestrus, and diestrus I/II) based on previously
published criteria (Marcondes et al., 2002; Feltenstein
et al., 2011) with a light microscope set at 10x magnification.
2.7. Experiment 1: oxytocin effects on meth-
primed reinstatement across the estrous cycle
Female rats (n = 10) self-administered meth along a FR 1
schedule of reinforcement throughout the self-administra-
tion phase. Following self-administration and extinction, rats
underwent nine meth-primed reinstatement tests with pre-
treatment of 0, 0.3, and 1 mg/kg oxytocin in order to deter-
mine an effective dose in females. When possible, rats were
tested during each of the phases of their estrous cycle
(estrus, proestrus, diestrus I/II). The number of animals that
tested in each condition follows: Control: Diestrus I/II n = 8,
Proestrus n = 4, Estrus n = 8; 0.3 mg/kg Oxytocin: Diestrus I/II
n = 10, Proestrus n = 8, Estrus n = 10; and 1 mg/kg Oxytocin:
Diestrus I/II n = 10, Proestrus n = 7, Estrus n = 10. Reinstate-
ment tests were conducted in randomized order with a
minimum of 2 extinction sessions occurring between tests,
or until subjects returned to criterion.
2.8. Experiment 2: oxytocin effects on meth
self-administration and reinstatement
Male (n = 15) and female (n = 17) rats initially self-adminis-
tered meth along a FR1 schedule of reinforcement (1 lever
press resulted in a meth infusion) until they reached criterion
of a minimum of 5 days with >10 infusions (with <25% change
in the number of infusions for 2 consecutive days). Rats then
moved to a FR3 schedule for a minimum of 3 days, followed by
a FR5 schedule for the remainder of the self-administration
sessions. Testing on the PR reinforcement schedule followed
stable responding on the FR5. Following these tests, extinc-
tion criterion was met and all rats underwent 3 types of
reinstatement tests in the following order: cue-induced,
meth-primed, and yohimbine-induced, each counterba-
lanced for oxytocin (1 mg/kg) or vehicle pretreatment for
a total of 6 reinstatement tests. Test order did not interact
with reinstatement responding. Between all reinstatement
tests, rats experienced a minimum of 2 extinction sessions, or
until extinction criterion was met.2.9. Experiment 3: oxytocin effects on sucrose
self-administration and reinstatement
Males (n = 7) and females (n = 12) underwent identical
procedures as rats in Experiment 2, with the following
exceptions. Instead of meth, sucrose pellets (45 mg,
Noyes pellets, Fisher Scientific) served as the primary
reinforcer. Sucrose rats did not undergo surgery. Addition-
ally, during sucrose primed reinstatement tests, rats
received one non-contingent pellet every 2 min for the
first 10 min of the session and one pellet every 30 min
thereafter.
2.10. Data analysis
The number of lever responses, breakpoint, and infusions
during the progressive ratio were the primary dependent
variables and were analyzed using analysis of variance
(ANOVA). For reinstatement testing during the estrous cycle,
lever responses were analyzed using a two-way ANOVA with
oxytocin dose and cycle phase as between subject factors.
Planned and post hoc comparisons were conducted using a
Bonferroni’s correction for family wise error when applic-
able, with the alpha set at 0.05. All data are expressed as the
mean  SEM.
3. Results
3.1. Experiment 1: estrous cycle effects on
meth-primed reinstatement with oxytocin
pretreatment
Fig. 1 depicts meth-primed reinstatement at three doses of
oxytocin (0, 0.3, and 1 mg/kg) during the three phases of the
estrous cycle (proestrus, diestrus I/II, estrus). Overall, oxy-
tocin dose did not interact with estrous cycle, nor was there a
main effect of estrous cycle. However, there was a main
effect of oxytocin dose [Fig. 1b, F(2,66) = 4.63, p < 0.05].
Specifically, 1 mg/kg oxytocin decreased responding relative
to vehicle [p < 0.05].
3.2. Experiment 2: oxytocin effects on meth
self-administration and reinstatement
Fig. 2 depicts the impact of oxytocin on PR performance
(lever presses, break points, and infusions) for males and
females during meth self-administration. Although sex did
not interact with oxytocin treatment [F(1,28) = 3.13,
p = 0.09], females had, overall, more active [Fig. 2A, sex
main effect, F(1,28) = 6.26, p < 0.05] and inactive (Table
1, sex main effect, F(7,28) = 4.48, p < 0.05] lever
responses as compared to males. Oxytocin decreased active
lever responding [treatment main effect, F(1,28) = 10.8,
p < 0.001]. However this decrease was only significantly
relevant to controls in females [Bonferroni, p < 0.05].
Consistently, females had a higher breakpoint than males
[Fig. 2B, sex main effect, F(1,28) = 5.68, p < 0.05], but sex
did not interact with oxytocin [F(1,28) = 2.42, p = 0.07].
Oxytocin decreased breakpoints [treatment main effect,
F(1,28) = 10.31, p < 0.001], but only significantly in
Figure 1 Meth-primed reinstatement to meth seeking in females following oxytocin pretreatment. (A) Active lever responding
during reinstatement by estrous cycle phase and dose of oxytocin. No effect of cycle phase was seen during meth-primed reinstatement
with or without oxytocin. (B) Active lever responding during reinstatement by dose of oxytocin. Oxytocin (1 mg/kg) significantly
decreased active lever responding as compared to vehicle (*p < 0.05).
Oxytocin mediation of meth seeking 2347females relative to saline controls [Bonferroni, p < 0.05].
The number of infusions earned during progressive ratio
responding did not interact between males and females
[F(1,28) = 3.41, p = 0.09]. Males and females earned similarFigure 2 Progressive ratio (PR) responding in males and females 
males and females after oxytocin or vehicle. Females responded more
decreased active lever responding for females, but not males. (B) Bre
to males and oxytocin (1 mg/kg) reduced the breakpoint in females, 
decreased the number of infusions for females, but not males. Signi
males and females treated with vehicle (yp < 0.05) are indicated.meth infusions (Fig. 2C), and oxytocin pretreatment
decreased infusions earned [treatment main effect,
F(1,28) = 14.08, p < 0.001]. This decrease in meth infusions
was only significant in females [Bonferroni, p < 0.05].during meth self-administration. (A) Active lever responding in
 on the active lever during the PR test relative to males. Oxytocin
akpoint during PR tests. Females had a higher breakpoint relative
but not males. (C) Number of infusions during PR tests. Oxytocin
ficant differences from same sex control (*p < 0.05) or between
Figure 3 Active lever responding during meth self-administration and subsequent reinstatement tests. (A) Active lever responding
during the last 5 days of self-administration and the last 2 days of extinction in males and females. (B) Active lever responding during
cue-induced reinstatement in males and females after oxytocin or vehicle. Females reinstated to conditioned cues to a greater extent
than males. Oxytocin decreased cue-induced reinstatement in females, but not males. (C) Active lever responding during meth-primed
reinstatement. Females responded more during the meth prime test than males. Oxytocin decreased meth-primed reinstatement in
both males and females. (D) Active lever responding during stress-induced reinstatement by yohimbine. Oxytocin decreased
yohimbine-induced reinstatement in males and females. Significant differences from same sex control (*p < 0.05) or between males
and females treated with vehicle (yp < 0.05) are indicated.
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statement data for meth self-administration in males and
females. Fig. 3A shows the average active lever responding
over the last 5 days of self-administration and the last 2 days
of extinction. No differences emerged between males and
females in active or inactive lever presses (see Table 1 forFigure 4 Progressive ratio (PR) responding for males and females du
active lever responding, (B) breakpoints, or (C) pellets earned duriinactive lever data). However, females (14.50  1.19) took
significantly more days to meet extinction criterion than
males (10.93  0.62) [t(27) = 2.7, p < 0.05].
After extinction, the rats were first tested on cue-induced
reinstatement tests (Fig. 3B). Active lever presses for males
and females varied according to treatment. Overall, femalesring sucrose self-administration. There were no differences in (A)
ng PR tests in males and females after oxytocin or vehicle.
Table 1 Mean (SEM) inactive lever responding during meth self-administration, progressive ratio, and reinstatement tests.
Females Males
Self-administration 50.8 (18.3) 29.3 (6.5)
Extinction 21.4 (10.4) 14.7 (3.5)
Females Males
Vehicle Oxytocin Vehicle Oxytocin
Progressive ratio+ 130.8 (36.7) 98.2 (30.5) 43.7 (12.9) 31.0 (10.1)
Reinstatement test
Cue* 31.7 (10.7) 10.4 (3.3) 15.4 (3.8) 10.9 (2.4)
Prime* 57.1 (21.3) 24.3 (12.5) 19.8 (4.2) 12.5 (3.9)
Yohimbine * 22.6 (8.9) 14.3 (4.1) 16.5 (3.3) 10.0 (2.0)
* Significant difference between oxytocin and vehicle.
+ Significant difference between males and females.
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males [sex main effect, F(1,24) = 11.55, p < 0.05] and oxy-
tocin attenuated active lever responding only in females
[sex  treatment interaction, F(1,24) = 7.35, p < 0.05, and
post hoc, p < 0.05]. Oxytocin also decreased inactive lever
responding [Table 1, treatment main effect, F(1,24) = 1.56,
p < 0.05]. During meth-primed reinstatement (Fig. 3C)
females had more active lever responses [sex main effect,
F(1,24) = 4.52, p < 0.05] and oxytocin decreased active
[treatment main effect, F(1,24) = 51.14, p < 0.0001] and
inactive [Table 1, treatment main effect, F(1,24) = 8.6,
p < 0.01] lever responding in both females and males. Rats
were then tested on a yohimbine stress induced reinstate-
ment test (Fig. 3D). During yohimbine-induced reinstate-
ment, females reinstated to a greater extent than males
[sex main effect, F(1,20) = 5.73, p < 0.05] and oxytocin
attenuated active [treatment main effect, F(1,20) = 16.87,
p < 0.001] and inactive [Table 1, treatment main effect,
F(1,22) = 4.35, p < 0.05] lever responding in both sexes.
3.3. Experiment 3: oxytocin effects on sucrose
self-administration and reinstatement
Fig. 4 depicts the impact of oxytocin on lever presses,
infusions, and break points during the PR tests for sucrose






Progressive ratio 70.3 (28.2) 37.4 (
Reinstatement test
Cue 16.4 (7.4) 9.3 (
Prime 11.5 (5.2) 8.8 (
Yohimbine 77.4 (37.1) 19.4 (differences or oxytocin effects on the number of active
(Fig. 4A) or inactive (Table 2) lever presses, break point
(Fig. 4B), or pellets earned (Fig. 4C).
Fig. 5A shows the average active lever responding over the
last 5 days of sucrose self-administration (when self-admin-
istration behavior had stabilized), and no differences were
seen between males and females. Extinction responding did
not differ during the last 2 days between sexes. Following
extinction, the rats were first tested on a cue-induced rein-
statement test (Fig. 5B). Females responded more on the
active lever than males [sex main effect, F(1,13) = 6.97,
p < 0.05]. Oxytocin did not affect responding in either
sex. On the sucrose prime test (Fig. 5C), oxytocin decreased
active lever responding in both females and males [treat-
ment main effect [F(1,13) = 8.61, p < 0.05]. In addition,
during the yohimbine-induced reinstatement test, oxytocin
attenuated active lever responding in both sexes [Fig. 5D,
F(1,13) = 8.01, p < 0.005]. Responding on the inactive
lever did not differ on any measure for sucrose-trained rats
(Table 2).
4. Discussion
Here, we have established that the ability of systemic oxy-
tocin to reduce reinstatement of meth seeking may be
dependent on sex and the specific type of relapse trigger.elf-administration, progressive ratio, and reinstatement tests.
ales Males
 (5.9) 28.4 (2.5)
 (2.7) 22.1 (0.6)
Males
in Vehicle Oxytocin
24.2) 36.6 (8.8) 28.9 (10.4)
5.0) 26.0 (7.6) 15.1 (5.4)
3.0) 14.7 (5.0) 13.4 (3.7)
16.3) 79.7 (36.4) 27.9 (13.2)
Figure 5 Active lever responding during sucrose self-administration and subsequent reinstatement tests in males and females
treated with oxytocin or vehicle. (A) Active lever responding during that last 5 days of self-administration and the last 2 days of
extinction in males and females. (B) Active lever responding during cue-induced reinstatement in males and females after oxytocin or
vehicle. Females reinstated to conditioned cues to a greater extent than males. Oxytocin decreased cue-induced reinstatement in
females, but not males. (C) Active lever responding during sucrose-primed reinstatement. Females responded more during the sucrose
prime test than males. Oxytocin decreased sucrose-primed reinstatement in both males and females. (D) Active lever responding
during stress-induced reinstatement by yohimbine. Oxytocin decreased yohimbine-induced reinstatement in males and females.
Significant differences from same sex control (*p < 0.05) or between males and females treated with vehicle (yp < 0.05) are indicated.
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motivation to take meth, as well as reward seeking in
response to conditioned reinforcers. The similarities
between sexes were evident by the ability of oxytocin to
decrease meth seeking in both males and females in response
to a drug prime and a pharmacological stressor. To date, only
one study exists (Holtz et al., 2012) that directly compared
the ability of a treatment compound (allopregnanolone or
modafinil) to block reinstatement to meth seeking in both
males and females. However, prior studies with rats have
clearly demonstrated pronounced differences between male
and female meth intake (Reichel et al., 2012), motivation to
self-administer meth (current report, Roth and Carroll,
2004), and reinstatement of meth seeking (Holtz et al.,
2012; Reichel et al., 2012).
In the first experiment, estrous cycle did not interact with
oxytocin during meth-primed reinstatement testing and
females reinstated to a meth prime regardless of cycle phase.
As such, neither meth-primed reinstatement nor attenuation
with oxytocin appeared to be influenced by circulating ovar-
ian hormones. However, PR responding and reinstatement
tests were conducted based on response criteria, rather than
estrous cycle for the females. Therefore, the possibility
remains that the reported sex differences may be due, in
part, to differential regulation of oxytocin receptor affinity,
surface expression, and/or coupling mechanisms by estrogen
and progesterone. For example, estrogen increased oxytocin
receptor affinity in the medial preoptic area of the hypotha-
lamus (Caldwell et al., 1994) and receptor density in the
ventromedial nucleus (Coirini et al., 1991). Additionally,progesterone increased oxytocin receptor density in limbic
structures (Patchev et al., 1993), which could subsequently
increase the effects of oxytocin in females relative to males.
Fluctuations in gonadal hormones may account for the sex
differences in motivation to take meth during the PR tests
and meth seeking during cue-induced reinstatement.
Oxytocin reduced responding for meth along the PR sche-
dule of reinforcement in females down to a level comparable
to males. However, motivation for sucrose was similar in
males and females regardless of pretreatment condition.
In males, oxytocin did not have an effect on either meth
or sucrose taking during the PR. A distinction between drug
and natural reward occurred in females, as oxytocin only
decreased meth taking, but not sucrose taking, during the
PR. Interestingly, females in general demonstrated greater
motivated meth taking, which is in line with previous self-
administration studies with meth (Roth and Carroll, 2004),
cocaine (Roberts et al., 1989), heroin (Cicero et al., 2002),
and alcohol (Peters et al., 2013). While we found the ability
of oxytocin to reduce motivation to obtain meth was specific
to females, a previous study showed that oxytocin (1 mg/kg)
decreased responding on a similar PR task in male rats
(Carson et al., 2010a). Although strain differences may exist
between studies, these contrasting findings in males likely
arise from several methodological differences. For example,
in our study, rats were maintained on a FR schedule of
reinforcement and two PR ratio tests were given in a counter-
balanced manner with a minimum of two days for intervening
stabilization. In contrast, rats in the earlier study transi-
tioned to and maintained their responding along a PR
Oxytocin mediation of meth seeking 2351schedule of reinforcement and oxytocin administration
occurred on five consecutive days with ascending doses. As
such, these repeated daily doses of oxytocin might have
resulted in a sensitized response to oxytocin. Also, rats
maintained along a PR schedule received fewer daily meth
infusions on average than rats in our study that were main-
tained along a FR. The increased meth intake for males may
have rendered them less susceptible to lower doses of oxy-
tocin (i.e., oxytocin’s efficacy may be related to total meth
intake).
Oxytocin only reduced cue-induced reinstatement in meth
females, indicating some specificity for sex and conditioning
of drug—cue associations. For example, in females, oxytocin
decreased responding for meth-conditioned cues, but not
sucrose. This difference indicates that oxytocin has some
degree of specificity to reduce relapse to drug related cues,
rather than those associated with natural reward. Alterna-
tively, different response rates between the meth and
sucrose studies provide a potential explanation for this dif-
ference. Specifically, the sucrose females received on aver-
age 561.8 (25.4) primary and secondary reinforcers (i.e.,
sucrose pellets and light + tone stimulus complex) during the
last 5 days of self-administration as compared to the meth
females that received 162.9 (10.5) reinforcers. Conse-
quently, this difference in response rate and reinforcement
history may have rendered sucrose females less susceptible
to oxytocin’s ability to attenuate cue-induced reward
seeking.
In the current study, females responded more to meth and
sucrose conditioned cues in comparison to males. Previous
studies have shown that females responded equally to males
in response to conditioned cues during reinstatement of
cocaine (Feltenstein et al., 2011; Zhou et al., 2012) or
nicotine (Feltenstein et al., 2012) seeking. Importantly,
these effects were evident when rats were trained and tested
along an FR1 schedule of reinforcement. Meth rats in our
study were trained and tested on an FR5 schedule of rein-
forcement, whereby the light + tone stimulus complex
occurred after every 5 active lever presses during the rein-
statement test. Male meth rats had low levels of reinstate-
ment on this test schedule relative to our experiences
typically observed with FR1 cue-induced reinstatement
(Reichel and See, 2010; Reichel et al., 2012), suggesting a
possible floor effect. In spite of the low reinstatement in
males, females demonstrated markedly more robust rein-
statement in the identical situation. Surprisingly, females
were impervious to the lean reinforcement schedule during
cue-induced reinstatement. This enhanced responding to
conditioned reinforcers suggests that females may entrain
the original associations to a greater degree than males,
indicating differences in interpretation of the associative
strength of the reward. Associative strength is defined as
the degree of strength of learning that occurs between a
conditioned stimulus (CS, i.e., light + tone) and the uncondi-
tioned stimulus (US, i.e., physiological effects of meth or
sucrose). Increased meth-cue and sucrose-cue reinstatement
in females may be due to increased salience or value of the
US, which imbues the associative strength of the CS. Support
for this notion comes from a demonstration that estrogen
enhanced conditioned learning in delay and trace condition-
ing paradigms (Shors et al., 2000). Since we utilized freely
cycling females with an intact hormonal system, fluctuationsin estrogen and progesterone levels during self-administra-
tion may have influenced the original associative processes.
Oxytocin was equally effective at reducing reinforcer-
primed reinstatement of meth and sucrose seeking, although
females reinstated to a greater extent to a meth prime than
males. This sex difference has been seen before and demon-
strates that, regardless of session length, females exhibit
enhanced meth seeking to a priming injection [current report
(Holtz et al., 2012; Reichel et al., 2012)]. Importantly, meth-
primed reinstatement did not depend upon estrous cycle
phase for females, nor did cycle interact with the ability
of oxytocin to reduce meth seeking. In fact, oxytocin reduced
prime-induced meth seeking during all cycle phases for
females. Further, oxytocin decreased sucrose seeking during
sucrose primed reinstatement tests. Taken together, oxyto-
cin decreased seeking for both meth and sucrose during the
reinstatement tests in both sexes. This effect suggests that
oxytocin decreased seeking for both drug and natural reward,
perhaps through similar mechanisms. Although the under-
lying mechanisms are beyond the scope of this study, one
suggestion relies on the interaction of oxytocin with the
dopamine system (Baskerville and Douglas, 2010). Oxytocin
may decrease the saliency of reward via interactions with
dopamine activity in regions known to be involved in drug
seeking. For example, in mice, oxytocin attenuated meth-
induced dopamine efflux in the nucleus accumbens (Qi et al.,
2009), and regulated meth-induced changes in extracellular
glutamate and g-aminobutyric acid (GABA) in mouse brain (Qi
et al., 2012). In rats, oxytocin decreased meth-induced Fos
expression in the nucleus accumbens core (Carson et al.,
2010b). Future studies will need to directly elucidate the
mechanism by which oxytocin attenuates drug seeking.
The route of systemic oxytocin administration results in a
more homologous comparison for therapeutic use, rather
than site specific brain infusions. However, peripheral admin-
istration of a neuropeptide raises the issue of the degree of
transfer across the blood brain barrier to exert a centrally
mediated effect (Landgraf et al., 1979). We suspect that
decreased meth seeking was primarily mediated through
actions in the brain and not via peripheral effects for several
reasons. First, peripherally administered oxytocin attenu-
ated cocaine induced sniffing behavior, which was subse-
quently blocked by intracerebroventricular administration
of an oxytocin antagonist (Sarnyai et al., 1991). Second,
peripherally administered oxytocin increased fos (a marker
of neuronal activation) expression in oxytocin cells of the
supraoptic and paraventricular nuclei of the hypothalamus
(Carson et al., 2010b). Finally, methamphetamine-induced
fos expression was decreased in the nucleus accumbens core
and subthalamic nucleus following peripheral oxytocin treat-
ment. Combined, these data demonstrate that peripherally
administered oxytocin can exert central actions.
In all subjects, oxytocin attenuated yohimbine-induced
reinstatement, suggesting a common mechanism for reduc-
tions in stress-induced reinstatement. Oxytocin produces
anxiolytic effects in humans (Macdonald and Macdonald,
2010) and animals (Neumann et al., 2000) through inhibition
of the hypothalamic—pituitary—adrenal axis, which is a sex
independent effect in rats (Neumann et al., 2000). The
pharmacological stressor, yohimbine, produced similar rein-
statement in both sexes of rats with a meth history. This
finding was somewhat surprising, given that female cocaine
2352 B.M. Cox et al.addicts are purportedly more likely to relapse to stressful life
events (McKay et al., 1996; Back et al., 2005). Although,
results have been somewhat mixed in animal models of
relapse with cocaine. While one study showed greater yohim-
bine-induced reinstatement in females relative to males
(Anker and Carroll, 2010), our laboratory previously reported
that sex differences in reinstatement only emerged when
cues were simultaneously presented in combination with
yohimbine (Feltenstein et al., 2011). In the current study,
we also found no sex differences in yohimbine-induced rein-
statement of sucrose seeking. Earlier reports showed that
yohimbine reinstated sucrose seeking in males (Ghitza et al.,
2006; Richards et al., 2008), but to our knowledge, this effect
has not been previously shown in females.
Although inactive lever presses were uniformly lower than
active lever presses, oxytocin reduced inactive lever presses
in rats with a history of meth self-administration, but not
sucrose. Changes in inactive lever responding could indicate
alternative strategies in exploratory drive for reward and/or
non-specific motor behavior. These options are unlikely,
however, as pilot data from our laboratory has found that
oxytocin (1 mg/kg, 30 min before test) does not reduce
meth-induced or basal motor activity beyond baseline values
(data not shown). Furthermore, oxytocin did not decrease
responding for sucrose during the PR test, suggesting an
effect specific to meth-experienced rats.
In conclusion, we report: (1) oxytocin reduced motivation
to self-administer meth in females, but not males; (2)
females responded more to conditioned reinforcers during
cue-induced reinstatement tests; and (3) sex similarities in
the ability of oxytocin to decrease meth and sucrose seeking
in response to either a meth prime or a pharmacological
stressor. Oxytocin appears to have the greatest influence on
meth-experienced females, decreasing motivation and
relapse in response to cue, meth prime, and yohimbine-
induced reinstatement. In contrast, oxytocin only impacted
males in response to meth and yohimbine-primed reinstate-
ment. Taken together, these results indicate that oxytocin or
oxytocin receptor agonists may be a promising pharma-
cotherapeutic treatment strategy for meth addiction in both
males and females in response to multiple relapse triggers.
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